RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at Annual Meeting GI 2016

Alan P. Venook, MD of University of California San Francisco discusses RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016

Advertisement Single Below Content

RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at Annual Meeting GI 2016

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at Annual Meeting GI 2016

Related Posts

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia